Trial Profile
A Multi-Center, Randomized, Parallel Dose-Finding, Safety Assessor-Blinded Trial to Explore the Efficacy, Safety and Pharmacokinetics of Four Doses of Org 25969 and Placebo in Pediatric and Adult Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Rocuronium bromide
- Indications Neuromuscular blockade
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme; NV Organon
- 26 Sep 2014 New trial record